sch772984 (MedChemExpress)
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
94
Structured Review
MedChemExpress
sch772984
Sch772984, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 20 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-11107)/PHA-665752/pm42323670-56-22-28
Average 94 stars, based on 20 article reviews
Sch772984, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 20 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-11107)/PHA-665752/pm42323670-56-22-28
Average 94 stars, based on 20 article reviews
sch772984 - by Bioz Stars,
2026-11
94/100 stars
Images
Related Articles
other:Article Title: Integrative Mendelian Randomization and Experimental Validation Unveil Novel Druggable Targets in Primary Biliary Cholangitis. Article Snippet: Journal Pre-proof Integrative Mendelian Randomization and Experimental Validation Unveil Novel Druggable Targets in Primary Biliary Cholangitis Yinling Li, Huanhuan Xie, Zhenjie Zhuang, Xin Fang, Wenjun Yang, Yan Luo, Jiangyi Hu, Wei Wang, Haitao Wang, Xiaobing Dou, Junping Shi, Jin Yang PII: S0014-2999(26)00257-8 DOI: https://doi.org/10.1016/j.ejphar.2026.178775 Reference: EJP 178775 To appear in: European Journal of Pharmacology Received Date: 11 August 2025 Revised Date: 2 March 2026 Accepted Date: 9 March 2026 Please cite this article as: Li, Y., Xie, H., Zhuang, Z., Fang, X., Yang, W., Luo, Y., Hu, J., Wang, W., Wang, H., Dou, X., Shi, J., Yang, J., Integrative Mendelian Randomization and Experimental Validation Unveil Novel Druggable Targets in Primary Biliary Cholangitis, European Journal of Pharmacology, https://doi.org/10.1016/j.ejphar.2026.178775.. This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form. Article Title: Systems modeling identifies phenotype-determining signaling pathways controlled by phosphatase PTPRJ in diverse receptor tyrosine kinase activation settings Article Snippet: The EGFR inhibitor gefitinib (LC Laboratories G4408), MET inhibitor PHA-665752 (Santa Cruz Biotechnology sc-203186), PI3K inhibitor GDC-0941 (Cayman Chemicals 1160), Article Title: Dual inhibition of HERs and PD-1 counteract resistance in KRAS G12C -mutant head and neck cancer Article Snippet: Inhibitors were purchased from following suppliers: AMG510 (HY-114277), MRTX849 (HY-130149), lapatinib (HY-50898), erlotinib (HY-50896), PHA665752 (HY-11107) afatinib (HY-10261) and Article Title: Umbilical cord mesenchymal stromal cells-derived HGF inhibits STING-mediated pyroptosis to alleviate cerebral ischemia/reperfusion injury via c-Met/β-catenin/RNF5 pathway. Article Snippet: To validate the role of HGF/c-Met, cells were treated with rhHGF (20 ng/mL, Peprotech, Rosemont, IL, USA), Control:Article Title: HHLA2 activates c-Met and identifies patients for targeted therapy in hepatocellular carcinoma Article Snippet: .. 31 Organoid drug response assay 32 Page | 16 The Western Blot:Article Title: Hepatocyte growth factor suppresses melanogenesis via ERK-dependent nuclear exclusion of MITF. Article Snippet: .. For western blot analysis, adherent cells were pretreated with HGF (20 ng/mL) for 1 h, followed by treatment with PD98059 (10 μM), SCH772984 (1 μM), |